Acthrel Market Report 2026

Acthrel Market Overview

• The Acthrel market growth in the historic period has been driven by clinical need for precise adrenal diagnostics, established role in hpa testing • Market expansion is supported by increasing endocrine disorder prevalence, improved diagnostic accuracy demand • Growth Driver: Diagnostic Testing Growth Boosts Acthrel Demand In Endocrine Disorder Diagnosis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Acthrel Market?

Acthrel (corticorelin ovine triflutate) is a synthetic version of corticotropin-releasing hormone (CRH) used in diagnostic testing of the hypothalamic-pituitary-adrenal (HPA) axis function. It aids in diagnosing adrenal insufficiency, differentiating between Cushing’s syndrome causes, and evaluating pituitary gland function in medical settings. The main applications of acthrel are the diagnosis of adrenal insufficiency, hypothalamic-pituitary-adrenal (HPA) axis testing, and medical research. Diagnosis of adrenal insufficiency involves a series of medical tests and evaluations to determine if the adrenal glands are producing adequate levels of hormones, primarily cortisol, to meet the body's needs. It is primarily used for adults and geriatric patients. Acthrel is distributed through hospitals and clinics as well as retail and specialty pharmacies, ensuring accessibility across healthcare settings.

What Is The Acthrel Market Growth Forecast?

The growth in the forecast period can be attributed to increasing endocrine disorder prevalence, improved diagnostic accuracy demand, expansion of specialty diagnostic centers, rising clinical research activity, adoption in advanced hospital laboratories. Major trends in the forecast period include increasing use in endocrine diagnostic testing, growing focus on accurate hpa axis evaluation, expansion of specialized hormonal diagnostics, improved clinical differentiation of cushing’s syndrome, rising use in advanced endocrinology centers.

Global Acthrel Market Segmentation

1) By Application: Diagnosis Of Adrenal Insufficiency, Hypothalamic-Pituitary-Adrenal (HPA) Axis Testing, Medical Research 2) By End User: Adult, Geriatric 3) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies

What Are The Drivers Of The Acthrel Market?

The rising demand for diagnostic testing is expected to propel the growth of the acthrel market going forward. Diagnostic testing refers to medical procedures used to identify or confirm the presence of a disease or condition in a patient. The increase in diagnostic testing can be attributed to factors such as advancements in medical technology, a growing focus on early disease detection, rising health awareness, and an aging population. Acthrel aids diagnostic testing by stimulating the pituitary gland to release adrenocorticotropic hormone (ACTH), enabling healthcare professionals to evaluate adrenal gland function and diagnose conditions like adrenal insufficiency or disorders related to the hypothalamic-pituitary-adrenal axis. For instance, in December 2024, according to the National Health Service, a UK-based government department, the number of diagnostic tests by activity has reached 2,544,809 in 2024, an increase from 2,312,030 in 2023. Therefore, the rising demand for diagnostic testing is driving the acthrel industry. The rising healthcare expenditure is expected to propel the growth of the acthrel markets going forward. Healthcare expenditure refers to the total amount of financial resources allocated or spent on healthcare services and goods within a specific period. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Acthrel contributes to rising healthcare expenditure by enabling accurate hypothalamic-pituitary-adrenal (HPA) axis testing, essential for diagnosing complex endocrine disorders such as adrenal insufficiency and Cushing's syndrome, thus driving increased investment in diagnostic tools, therapeutic interventions, and specialized healthcare services. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the acthrel industry. The growing incidence of endocrine diseases is expected to drive the acthrel market going forward. Endocrine diseases are medical conditions that affect the endocrine glands, leading to imbalances in hormone production and regulation, impacting overall body functions. The growing incidence of endocrine diseases is driven by unhealthy lifestyle patterns, as poor diet, inactivity, and chronic stress disrupt hormonal balance and increase the risk of metabolic and glandular disorders. Acthrel supports the diagnostic evaluation of the hypothalamic-pituitary-adrenal (HPA) axis, enabling accurate identification and management of adrenal and related endocrine disorders in response to the growing prevalence of endocrine diseases. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the growing incidence of endocrine diseases is driving the acthrel industry.

Key Players In The Global Acthrel Market

Major companies operating in the acthrel market are Ferring Pharmaceuticals

Regional Insights

North America was the largest region in the acthrel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Acthrel Market?

The acthrel market consists of sales of products such as lyophilized powder intended for injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acthrel Market Report 2026?

The acthrel market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acthrel industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.